Original ResearchFull Report: Clinical—LiverAdjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest These authors disclose the following: Joon Hyeok Lee has received grants from Green Cross Cell Corp, Bukwang Pharmaceuticals, Pfizer, JW Creagene, and GlaxoSmithKline, has received lecture fees from Bayer Pharmaceuticals, Gilead Science, Bukwang Pharmaceuticals, and GlaxoSmithKline, and serves as an advisory board member of Gilead Science and Bristol-Myers Squibb; Jung-Hwan Yoon has received a research grant from Bayer HealthCare Pharmaceuticals; Young-Suk Lim has received research grants from Bayer HealthCare Pharmaceuticals and Gilead Science; Jong Eun Yeon has received research grants from Yuhan Pharmaceuticals and Jeil Pharmaceuticals, and serves as an advisory board member of Bayer Korea; Yoon Jun Kim has received research grants from Bristol-Myers Squibb, Roche, JW Creagene, Bukwang Pharmaceuticals, Handok Pharmaceuticals, Hanmi Pharmaceuticals, Yuhan Pharmaceuticals, and Pharmaking, and has received lecture fees from Bayer HealthCare Pharmaceuticals, Gilead Science, MSD Korea, Yuhan Pharmaceuticals, Samil Pharmaceuticals, CJ Pharmaceuticals, Bukwang Pharmaceuticals, and Handok Pharmaceuticals; Kang Mo Kim has received research grants from AstraZeneca, Yuhan Pharmaceuticals, and Il-Dong Pharmaceuticals, has received lecture fees from Bayer HealthCare Pharmaceuticals, MSD, and GlaxoSmithKline, and has received a consulting fee from Bayer HealthCare Pharmaceuticals; Geum-Youn Gwak has received lecture fees from Bristol-Myers Squibb, JW Creagene, Handok Pharmaceuticals, and MSD Korea; and Su Jong Yu has received a lecture fee from Bayer HealthCare Pharmaceuticals. The remaining authors disclose no conflicts.
Funding Supported by Green Cross Cell Corp (Seoul, Korea). This study was designed by the sponsor in conjunction with the principal academic investigators. Data were managed in parallel by the sponsor and the principal investigators.
Authors names in bold designate shared co-first authors.
- ∗
Authors share co-first authorship.